Live from the NIH registry
Studies recruiting near Elk Grove right now
Top 25 of 620 recruiting studies, sorted by proximity — each links to its official registry page
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation, HER2- Negative Breast Cancer
Phase 3
Interventional 540 participants sought
University of California, Davis Comprehensive Cancer Center — Sacramento, California (12.9 mi)
· Sponsor: Relay Therapeutics, Inc.
Treatment of Moderate to Severe Refractory Crohn's Disease
Crohns Disease
Phase 1, Phase 2
Interventional 39 participants sought
University of California, Davis — Sacramento, California (12.9 mi)
· Sponsor: Tr1X, Inc.
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Neovascular Age-related Macular Degeneration
Phase 4
Interventional 188 participants sought
Retinal Consultants Med Group — Sacramento, California (12.9 mi)
· Sponsor: Genentech, Inc.
Outcomes of Running Locking Suture vs Standard Running Suture in Surgical Wounds
Scarring
N/A
Interventional 50 participants sought
University of California, Davis - Dermatology Department — Sacramento, California (12.9 mi)
· Sponsor: University of California, Davis
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Phase 3
Interventional 1,524 participants sought
University of California Davis Comprehensive Cancer Center — Sacramento, California (12.9 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy
Invasive Mould Infection
Phase 2
Interventional 60 participants sought
UC Davis Medical Center — Sacramento, California (12.9 mi)
· Sponsor: Elion Therapeutics, Inc.
Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection
Viral Pneumonia
Phase 2
Interventional 550 participants sought
University of California - Davis — Sacramento, California (12.9 mi)
· Sponsor: Synairgen Research Ltd.
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
Geographic Atrophy, Macular Degeneration
N/A
Observational 500 participants sought
Retinal Consultants Medical Group Inc — Sacramento, California (12.9 mi)
· Sponsor: Astellas Pharma Global Development, Inc.
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
Acute Ischemic Stroke
Phase 2, Phase 3
Interventional 740 participants sought
Corxel Investigational Site — Sacramento, California (12.9 mi)
· Sponsor: Corxel Pharmaceuticals
Coordinating Outpatient bupreNorphiNe for Emergency Care and Continuing Treatment
Opioid Use Disorder
N/A
Interventional 3,492 participants sought
University of California Davis Emergency Department — Sacramento, California (12.9 mi)
· Sponsor: University of California, Davis
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Phase 2
Interventional 188 participants sought
Sutter Cancer Centers Radiation Oncology Services-Roseville — Roseville, California (23.8 mi)
· Sponsor: National Cancer Institute (NCI)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Relapsed Refractory Multiple Myeloma
Phase 3
Interventional 508 participants sought
Research Site — Sacramento, California (12.9 mi)
· Sponsor: AstraZeneca
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma
Phase 1, Phase 2
Interventional 37 participants sought
University of California Davis Comprehensive Cancer Center — Sacramento, California (12.9 mi)
· Sponsor: National Cancer Institute (NCI)
Sacramento Clinical High Risk for Psychosis Stepped-Care Program
Clinical High Risk for Psychosis, Ultra High Risk for Psychosis
N/A
Interventional 223 participants sought
River Oak Center for Children — Elk Grove, California (0.8 mi)
· Sponsor: University of California, Davis
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer
Phase 3
Interventional 480 participants sought
University of California Davis Comprehensive Cancer Center — Sacramento, California (12.9 mi)
· Sponsor: ArriVent BioPharma, Inc.
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
Atopic Dermatitis
Phase 3
Interventional 180 participants sought
Integrative Skin Science and Research — Sacramento, California (12.9 mi)
· Sponsor: Organon and Co
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
Growth Hormone Deficiency
N/A
Observational 500 participants sought
Ascendis Investigational Site — Sacramento, California (12.9 mi)
· Sponsor: Ascendis Pharma Endocrinology Division A/S
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Ganglioneuroblastoma, Nodular, Neuroblastoma
Phase 3
Interventional 478 participants sought
Sutter Medical Center Sacramento — Sacramento, California (12.9 mi)
· Sponsor: National Cancer Institute (NCI)
MOTION Clinical Trial
Osteoarthritis, Knee
N/A
Interventional 100 participants sought
Sutter Health — Sacramento, California (12.9 mi)
· Sponsor: Moximed
Clinical Trial Exploring the Outpatient Treatment of Phantom Limb Pain With Ketamine Administration in a Six Month Study With a Minimum Remission Period of 7 Days Between Treatment Session. 25-30 Subjects With an Ongoing History of Significant PLP.--FDA and IRB Approved.
Phantom Limb Syndrome With Pain
Phase 2, Phase 3
Interventional 30 participants sought
Shamynds — Sacramento, California (12.9 mi)
· Sponsor: The Ketamine Research Foundation
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma
Phase 3
Interventional 1,450 participants sought
Mercy Cancer Center - Elk Grove — Elk Grove, California (0.8 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
Small Bowel Cancer, Colorectal Cancer
N/A
Interventional 300 participants sought
University of California, Davis Comprehensive Cancer Center — Sacramento, California (12.9 mi)
· Sponsor: University of California, Davis
Effects of PFC tDCS on Cognitive Control, Attention Lapses and Coordinated Neural Activity in the Theta and Alpha Bands
Healthy
N/A
Interventional 75 participants sought
Imaging Research Center — Sacramento, California (12.9 mi)
· Sponsor: University of California, Davis
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Phase 3
Interventional 720 participants sought
Research Site — Sacramento, California (12.9 mi)
· Sponsor: Arcus Biosciences, Inc.
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
Aneurysm, Aneurysm, Intracranial
N/A
Interventional 183 participants sought
University of California Davis Health — Davis, California (21.2 mi)
· Sponsor: Stryker Neurovascular